IHU Infiny
Recherche
Contact
Faire un don

Menu

Événements

Faire un don

Recherche

Scientific publications

On this page, explore all the scientific publications authored by IHU Infiny researchers aimed at advancing the understanding and care of inflammatory bowel diseases.

Academic Journals

Dziegielewski et al (2025). IL-23p19 Antagonists vs. Ustekinumab for Treatment of Crohn’s Disease: A Meta-analysis of Randomized Controlled Trials . The American Journal Of Gastroenterology.

Moulin et al (2025). The role of the immune system in osteoarthritis: mechanisms, challenges and future directions. Nature Reviews Rheumatology.

Fasulo et al (2024). Advancing Colorectal Cancer Prevention in Inflammatory Bowel Disease (IBD): Challenges and Innovations in Endoscopic Surveillance. Cancers, 17(1), 60.

Allocca et al (2025). Systematic Review on definitions of Intestinal Ultrasound Treatment Response and Remission in Inflammatory Bowel Disease. Journal Of Crohn S And Colitis.

Centanni et al (2025). Advancing Therapeutic Targets in IBD: Emerging Goals and Precision Medicine Approaches. Pharmaceuticals, 18(1), 78 .

Vieujean et al (2025). Understanding the therapeutic toolkit for inflammatory bowel disease. Nature Reviews Gastroenterology & Hepatology.

Temido et al (2025). Overcoming the challenges of overtreating and undertreating inflammatory bowel disease. The Lancet. Gastroenterology & Hepatology.

D’Amico et al (2025). Unlocking hope: The future of ustekinumab biosimilars in Crohn’s disease treatment. United European Gastroenterology Journal.

Honap, Danese and Peyrin-Biroulet (2024c). Target Trial Emulation: Improving the Quality of Observational Studies in Inflammatory Bowel Disease Using the Principles of Randomized Trials. Inflammatory Bowel Diseases.

Sequier, Caron, Loeuille, et al (2024). Systematic review: Methotrexate-A poorly understood and underused medication in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics, 60(6), 686-700.

Vieujean and Peyrin-Biroulet (2024). Pharmacokinetics of S1P receptor modulators in the treatment of ulcerative colitis. Expert Opinion On Drug Metabolism & Toxicology, 20(9), 881-892.

Parigi, Solitano, et al (2024). Defining mucosal healing in randomized controlled trials of inflammatory bowel disease: A systematic review and future perspective. United European Gastroenterology Journal, 12(9), 1266-1279.

Temido, Honap, Danese, et al (2024). Nested Randomized Controlled Trials in Large Databases: An Opportunity for Inflammatory Bowel Disease? Journal Of Crohn S And Colitis.

Solitano, Jairath, et al (2024). TL1A inhibition for inflammatory bowel disease treatment: From inflammation to fibrosis. Med, 5(5), 386-400.

Fanizza et al (2024). Inflammatory Bowel Disease and Colorectal Cancer. Cancers, 16(17), 2943.

D’Amico, Magro, et al (2024). Practical management of mild-to-moderate ulcerative colitis: an international expert consensus. Expert Review Of Gastroenterology & Hepatology, 18(8), 421-430.

Lusetti et al (2024). Positioning risankizumab in the treatment algorithm of moderate-to-severe Crohn’s disease. Immunotherapy, 16(9), 581-595.

Faggiani et al (2024). Evaluating the pharmacokinetics of upadacitinib for the treatment of moderate-to-severe Crohn’s disease. Expert Opinion On Drug Metabolism & Toxicology, 20(5), 297-305.

D’Amico, Lusetti, et al (2024). MMX mesalamine in ulcerative colitis: Major advantages towards classical mesalamine formulations. Digestive And Liver Disease, 56(9), 1425-1432.

Honap, Zou, Danese, et al (2024). Personalized (N-of-1) Clinical Trials for Inflammatory Bowel Disease: Opportunities and Challenges. Clinical Gastroenterology And Hepatology.

Hanzel et al (2024). Differences between the 2016 and 2022 FDA guidance – implications for design and interpretation of clinical trials in ulcerative colitis. Crohn S & Colitis 360, 6(2).

Moreira et al (2024). Assessment of outcomes in Crohn’s disease: A systematic review of randomized clinical trials to inform a multiple outcome framework. United European Gastroenterology Journal, 12(9), 1280-1291.

Solitano, Yuan, et al (2024). Efficacy and safety of Advanced Combination Treatment in immune-mediated inflammatory disease: A systematic review and meta-analysis of randomized controlled trials. Journal Of Autoimmunity, 149, 103331.

Faggiani, D’Amico, Furfaro, et al (2024). Small Bowel Cancer in Crohn’s Disease. Cancers, 16(16), 2901.

Fanizzi et al (2024). The Role of Fecal Microbiota Transplantation in IBD. Microorganisms, 12(9), 1755.

Fanizzi, Allocca, et al (2024). Raising the bar in ulcerative colitis management. Therapeutic Advances In Gastroenterology, 17.

Bencardino et al (2024). IgG4 in the gut: Gastrointestinal IgG4-related disease or a new subtype of inflammatory bowel disease. Autoimmunity Reviews, 24(2), 103720.

Clough et al (2024). Biomarkers in inflammatory bowel disease: a practical guide. Therapeutic Advances In Gastroenterology, 17.

Lagrange et al (2024b). Implications of von Willebrand Factor in Inflammatory Bowel Diseases: Beyond Bleeding and Thrombosis. Inflammatory Bowel Diseases, 30(12), 2500-2508.

Temido, Honap, Bursztejn, et al (2024b). Drug-Induced Acne in Inflammatory Bowel Disease: A Practical Guide for the Gastroenterologist. The American Journal Of Gastroenterology.

Kotze et al (2024). Acute severe ulcerative colitis: defining the precise moment for colectomy. Expert Review Of Gastroenterology & Hepatology, 1-10.

Bernardi et al (2024). Role of Probiotics in the Management of Patients with Ulcerative Colitis and Pouchitis. Microorganisms, 13(1), 19.

Caron et al (2023). Caron, B., Jairath, V., Laurent, V., Stoker, J., Laghi, A., D’Haens, G. R., Danese, S., & Peyrin-Biroulet, L. (2023). Defining Magnetic Resonance Imaging Treatment Response and Remission in Crohn’s Disease: A Systematic Review. Journal Of Crohn S And Colitis, 18(1), 162-170.

Fanizza et al (2023). The Role of IL-23 Inhibitors in Crohn’s Disease. Journal Of Clinical Medicine, 13(1), 224.

D’Amico, Solitano, et al (2023). Practical Management of Biosimilar Use in Inflammatory Bowel Disease (IBD): A Global Survey and an International Delphi Consensus. Journal Of Clinical Medicine, 12(19), 6350.

Vuyyuru et al (2023). Scoring Indices for Perianal Fistulising Crohn’s Disease: A Systematic Review. Journal Of Crohn S And Colitis, 18(6), 836-850.

D’Amico, Peyrin-Biroulet, et al (2023). Disease clearance in ulcerative colitis: Is the ultimate therapeutic target? United European Gastroenterology Journal, 11(8), 717-719.

Fundamental Research

Mariette et al (2025). Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes. RMD Open, 11(1), e005033.

Kordahi et al (2025). Mucus-penetrating microbiota drive chronic low-grade intestinal inflammation and metabolic dysregulation. Gut Microbes, 17(1).

Rytter et al (2025b). In vitromicrobiota model recapitulates and predicts individualised sensitivity to dietary emulsifier. Gut, gutjnl-333925.

Madel et al (2024). Dysregulated myeloid differentiation in colitis is induced by inflammatory osteoclasts in a TNFα-dependent manner. Mucosal Immunology.

Lagrange et al (2024). Implications of von Willebrand Factor in Inflammatory Bowel Diseases: Beyond Bleeding and Thrombosis. Inflammatory Bowel Diseases, 30(12), 2500-2508.

Rubin et al (2024). Deployment of an Artificial Intelligence Histology Tool to Aid Qualitative Assessment of Histopathology Using the Nancy Histopathology Index in Ulcerative Colitis. Inflammatory Bowel Diseases.

Schellenberg et al (2023). The Role of Platelets and von Willebrand Factor in the Procoagulant Phenotype of Inflammatory Bowel Disease. Journal Of Crohn S And Colitis, 18(5), 751-761.

Clinical Research

Vermeire et al (2025). Cardiovascular events observed among patients in the etrasimod clinical programme: an integrated safety analysis of patients with moderately to severely active ulcerative colitis. BMJ Open Gastroenterology, 12(1), e001516.

Sands et al (2025). Tamuzimod in patients with moderately-to-severely active ulcerative colitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 induction trial. The Lancet. Gastroenterology & Hepatology.

Panaccione et al (2025). Risankizumab Efficacy and Safety Based on Prior Inadequate Response or Intolerance to Advanced Therapy: Post Hoc Analysis of the INSPIRE and COMMAND Phase 3 Studies. Journal Of Crohn S And Colitis.

Honap et al (2025). Anti-tumor Necrosis Factor Drug Concentration Is Not Associated with Disease Outcomes in Pouchitis: A Retrospective, International Study. Digestive Diseases And Sciences.

Olivera et al (2025). Comparative Improvement in Health-Related Quality of Life with Advanced Therapies for Moderate-to-Severe Crohn’s Disease: A Network Meta-Analysis. The American Journal Of Gastroenterology.

Quilliot, D., Bonsack, O., Mahmutovic, M., Peyrin-Biroulet, L., & Caron, B. (2024). Exclusion diet and fasting practices in patients with inflammatory bowel disease: impact on nutritional status. Clinical Nutrition ESPEN.

Amiot et al (2024). Top-down infliximab plus azathioprine versus azathioprine alone in patients with acute severe ulcerative colitis responsive to intravenous steroids: a parallel, open-label randomised controlled trial, the ACTIVE trial. Gut.

Mancheron et al (2024). Development and Validation of a Sexual Quality of Life Score for Youths with Inflammatory Bowel Disease. Journal Of Crohn S And Colitis.

D’Amico et al (2024). Drug Optimization in Patients with Mild-to-Moderate Ulcerative Colitis: A Global Survey. Journal Of Clinical Medicine, 13(9), 2510.

Jairath et al (2024). Determining the optimal treatment target in patients with ulcerative colitis: rationale, design, protocol and interim analysis for the randomised controlled VERDICT trial. BMJ Open Gastroenterology, 11(1).

Hunaut et al (2024). Long-Term Neoplastic Risk Associated With Colorectal Strictures in Crohn’s Disease: A Multicenter Study. Gastro Hep Advances, 3(6), 731-737.

Peyrin-Biroulet et al (2024). Shorter Crohn’s Disease Duration Is Associated With Better Clinical and Endoscopic Outcomes With Risankizumab in Phase 3 Studies. Gastro Hep Advances, 3(4), 539-550.

Wespi et al (2024). Fecal urgency and incontinence in inflammatory bowel disease perceived by physician and patient: Results from the Swiss fecal urgency survey. United European Gastroenterology Journal.

Dulai et al (2024). Clinical Trial Design Considerations for Hospitalised Patients With Ulcerative Colitis Flares and Application to Study Hyperbaric Oxygen Therapy in the NIDDK HBOT-UC Consortium. Alimentary Pharmacology & Therapeutics , 60(11-12), 1512-1524.

Swaminathan et al (2024). Development and investigation of a non-invasive disease severity index for inflammatory bowel disease. Journal Of Crohn S And Colitis.

Peyrin-Biroulet et al (2024). An artificial intelligence-driven scoring system to measure histological disease activity in ulcerative colitis. United European Gastroenterology Journal, 12(8), 1028-1033.

Sands et al (2024). Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study. Inflammatory Bowel Diseases.

Solitano et al (2024). Placebo rates in Crohn’s disease randomized clinical trials: An individual patient data meta-analysis. Gastroenterology.

D’Amico, Massimino, et al (2024). An international multicentre study of SwiTching from Intravenous to subcutaneous inflixiMab and vEdolizumab in inflammatory bowel diseases: The TIME study. European Journal Of Clinical Investigation, 54(11).

Vermeire et al (2024). Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials. Journal Of Crohn S And Colitis.

Magro et al (2024). Endoscopic, Histologic, and Composite Endpoints in Patients with Ulcerative Colitis Treated with Etrasimod. Clinical Gastroenterology And Hepatology.

Parigi et al (2024). Prevalence, characteristics, management, and outcomes of difficult-to-treat inflammatory bowel disease. Journal Of Crohn S And Colitis.

D’Amico, Peyrin-Biroulet, et al (2024). Benefits of Biosimilars in the Management of Patients with Inflammatory Bowel Disease: An International Survey. Journal Of Clinical Medicine, 13(11), 3069.

Estevinho et al (2024). Network Meta-Analysis: Histologic and Histo-Endoscopic Improvement and Remission With Advanced Therapy in Ulcerative Colitis. Alimentary Pharmacology & Therapeutics, 60(10), 1276-1292 .

Sands, Feagan, et al (2024). Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis. New England Journal Of Medicine, 391(12), 1119-1129.

Peyrin-Biroulet, Panaccione, et al (2024). Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn’s Disease Regardless of Prior Biologic Exposure. Clinical Gastroenterology And Hepatology, 22(10), 2096-2106.

Sands, D’Haens, Clemow, Irving, Johns, Gibble, Abreu, Lee, Hisamatsu, Kobayashi, Dubinsky, Vermeire, Siegel, Peyrin-Biroulet, Moses, Milata, Arora, et al. (2024). Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study. Inflammatory Bowel Diseases, 30(12), 2245-2258.

Danese et al (2024). Clinical Trial: A Pragmatic Randomised Controlled Study to Assess the Effectiveness of Two Patient Management Strategies in Mild to Moderate Ulcerative Colitis-The OPTIMISE Study. Journal Of Clinical Medicine, 13(17), 5147.

Schreiber et al (2024). Distinct trajectories of symptomatic response in ulcerative colitis during filgotinib therapy: A post hoc analysis from the SELECTION study. United European Gastroenterology Journal, 12(9), 1243-1255.

Honap et al (2024). Target Trial Emulation: Improving the Quality of Observational Studies in Inflammatory Bowel Disease Using the Principles of Randomized Trials. Inflammatory Bowel Diseases.

Caron et al (2024). Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID. Therapeutic Advances In Gastroenterology, 17.

Honap, Agrinier, et al (2024). Disease prevention trials in IBD: feasibility to future outlook. Nature Reviews Gastroenterology & Hepatology.

Temido et al (2024). Drug-Induced Acne in Inflammatory Bowel Disease: A Practical Guide for the Gastroenterologist. The American Journal Of Gastroenterology.

Sequier et al (2024). Clinical experience of using biosimilars in Crohn’s disease and their effectiveness. Expert Opinion On Biological Therapy, 1-25.

Caron, Honap, et al (2024). Epidemiology of Inflammatory Bowel Disease across the Ages in the Era of Advanced Therapies. Journal Of Crohn S And Colitis, 18(Supplement_2), ii3-ii15.

Olivera et al (2024). Preventing and managing cardiovascular events in patients with inflammatory bowel diseases treated with small-molecule drugs, an international Delphi consensus. Digestive And Liver Disease, 56(8), 1270-1280.

Honap, Sands, et al (2024). Basket, Umbrella, and Platform Trials: The Potential for Master Protocol-Based Trials in Inflammatory Bowel Disease. Gastroenterology, 167(4), 636-642.e2.

Caron, Habert, et al (2024). Difficult-to-treat inflammatory bowel disease: Effectiveness and safety of 4th and 5th lines of treatment. United European Gastroenterology Journal, 12(5), 605-613.

Feagan et al (2024). Long-term safety and efficacy of filgotinib for the treatment of moderately to severely active ulcerative colitis: Interim analysis from up to 4 years of follow-up in the SELECTION open-label long-term extension study. Alimentary Pharmacology & Therapeutics, 60(5), 563-584.

Fumery et al (2024). Long-term Outcome of Risankizumab in Crohn’s Disease: a Real-world GETAID Study. Clinical Gastroenterology And Hepatology, 22(12), 2451-2458.e1.

Honap, Jairath, et al (2024). Acute severe ulcerative colitis trials: the past, the present and the future. Gut, 73(10), 1763-1773.

Honap, Jairath, Danese, et al (2024). Navigating the complexities of drug development for inflammatory bowel disease. Nature Reviews Drug Discovery, 23(7), 546-562.

Cosquer et al (2024). Risk of incident cancer in patients with Inflammatory Bowel Disease with prior breast cancer: a multicenter cohort study. Clinical Gastroenterology And Hepatology.

D’Haens et al (2024). Vedolizumab to prevent postoperative recurrence of Crohn’s disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial. The Lancet. Gastroenterology & Hepatology.

Honap, Jairath, Sands, et al (2024b). Acute Severe Ulcerative Colitis: An International Delphi Consensus on Clinical Trial Design and Endpoints. Clinical Gastroenterology And Hepatology.

Danese, Rothenberg, et al (2024). A randomized phase 2 study of efmarodocokin alfa, an IL-22 agonist, versus vedolizumab in patients with ulcerative colitis. Clinical Gastroenterology And Hepatology.

Rubin, Allegretti, et al (2024b). Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies. The Lancet.

Solitano, Hogan, et al (2024b). Placebo rates in Crohn’s disease randomized clinical trials: An individual patient data meta-analysis. Gastroenterology.

Solitano et al (2023). Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study. Autoimmunity Reviews, 23(3).

Peyrin-Biroulet et al (2023). The Impact of the COVID-19 Pandemic on Patients with Ulcerative Colitis: Results from a Global Ulcerative Colitis Narrative Patient Survey. Advances In Therapy, 41(2), 598-617.

Swaminathan et al (2023). The Disease Severity Index for Inflammatory Bowel Disease Is a Valid Instrument that Predicts Complicated Disease. Inflammatory Bowel Diseases, 30(11), 2064-2075. .

Verstockt et al (2023). The Safety, Tolerability, Pharmacokinetics, and Clinical Efficacy of the NLRX1 agonist NX-13 in Active Ulcerative Colitis: Results of a Phase 1b Study. Journal Of Crohn S And Colitis, 18(5), 762-772.

Parigi et al (2023). Efficacy, Safety, and Concerns on Microbiota Modulation, Antibiotics, Probiotics, and Fecal Microbial Transplant for Inflammatory Bowel Disease and Other Gastrointestinal Conditions: Results from an International Survey. Microorganisms, 11(11), 2806.

Barchi et al (2023). Leaving behind the Mucosa: Advances and Future Directions of Intestinal Ultrasound in Ulcerative Colitis. Journal Of Clinical Medicine, 12(24), 7569.

Solitano, Schaeffer, et al (2023). Reliability and Responsiveness of Histologic Indices for the Assessment of Crohn’s Disease Activity. Clinical Gastroenterology And Hepatology, 22(9), 1898-1907.e25.

Barchi, D’Amico, et al (2023). Recent advances in the use of ultrasound in Crohn’s disease. Expert Review Of Medical Devices , 20(12), 1119-1129.

D’Amico et al (2023). Management and treatment optimization of patients with mild to moderate ulcerative colitis. Expert Review Of Clinical Immunology, 20(3), 277-290.

Bencardino et al (2023). Efficacy and Safety of S1P1 Receptor Modulator Drugs for Patients with Moderate-to-Severe Ulcerative Colitis. Journal Of Clinical Medicine, 12(15), 5014.

Peyrin-Biroulet, Allegretti, et al (2023). Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study. Gastroenterology, 165(6), 1443-1457.

Vieujean et al (2023). Analysis of Clinical Trial Screen Failures in Inflammatory Bowel Diseases [IBD]: Real World Results from the International Organization for the study of IBD. Journal Of Crohn S And Colitis, 18(4), 548-559.

Honap and Peyrin-Biroulet (2023). Review article : Externally derived control arms-An opportunity for clinical trials in inflammatory bowel disease ? Alimentary Pharmacology & Therapeutics, 58(7), 659-667.

Schreiber et al (2023). Defining Comprehensive Disease Control for Use as a Treatment Target for Ulcerative Colitis in Clinical Practice: International Delphi Consensus Recommendations. Journal Of Crohn S And Colitis, 18(1), 91-105.

Honap et al (2023). An update on the safety of long-term vedolizumab use in inflammatory bowel disease. Expert Opinion On Drug Safety, 22(9), 767-776.

Honap, Danese, et al (2023). Are All Janus Kinase Inhibitors for Inflammatory Bowel Disease the Same? PubMed, 19(12), 727-738.

Berre et al (2023). Ulcerative colitis. The Lancet, 402(10401), 571-584.

Rechercher
Faire un don